−4.4259USD
1.564MUSD
39.611MUSD
4.021M
About JanOne Inc.
Sector
Industry
CEO
Antonios Isaac
Website
Headquarters
Las Vegas
Employees (FY)
207
Founded
1976
ISIN
US47089W1045
JanOne, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.
How to trade $JAN for max profit today.Hi traders, we have a trading idea to share with you.
The idea is for $JAN stock. The stock is currently above $ 4 (a support level) with upward momentum after reporting patent issuance for artery treatment.
In addition, the stock has a great upside if it will break through the trend line built on t
JAN - Will it hold?Hello there,
Jan is in a very strong support area, we will enter it for bouncing from this area.
Our SL will be breaking the line, and target as in the chart.
Cheers.
$JAN Explosion ready low floater. perfect chart!I have been stalking this stock for a very long time. Same as my previous pick, $APOP that exploded today, it has all of the criteria I am looking for. With such a small float this may go much higher than people may wish for. Good luck.
JANJanone Inc (NASDAQ:JAN) I have been accumulating this stock. The company announced last week that it has entered into a definitive agreement to sell its legacy recycling subsidiary, ARCA Recycling, to Virland Johnson, JanOne’s Chief Financial Officer, for an aggregate purchase price of approximately
$JAN to Sell its Legacy Recycling Business for $25 MillionJanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD)
The transaction is expected to close on
JAN short playJAN sold one of it's legacy subsidiaries to it's own CFO for ~$25M. Expected to close on or before August 18, 2021, according to Seeking Alpha
Downward trend makes it ripe for some short play
Watch the quick pop up due to selling pressure, buy at tip and sell once the dip happens
Somethingggggggg
hero to a tragic, long term JanOne Inc. develops treatments for conditions that cause severe pain. The company, through its non-addictive pain-relieving drugs, focuses on reduction for need of opioid prescriptions to treat disease associated pain that can lead to opioid abuse.
$JAN Is Our Low-Float Nasdaq Listed Biotech Alert. JanOne Inc. (NASDAQ: JAN)
Alert Price: $7.63
Float: 1.38M
Please turn your immediate attention to JanOne Inc. (NASDAQ: JAN).
JAN could be the next pharma stock to take Wall St. by storm.
The company is focused on finding treatments for conditions that cause severe pain and bringing to market drugs
JAN: patterns to exploitThis thing gaps up between 80%-40%% every month it seems like. The buy zone is consistently the .78 FIB level which I have marked on the chart. Waiting for price to hit the zone for a buy. This is probably the most predictable stock I've come across. Exploit it while you can.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
